Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2001

View Archived Issues

Novartis R&D day 2001: solid platform for sustained growth

Human monoclonal antibody LymphoStat-B enters clinical testing for autoimmune disease

Phase III trial plans announced for secretin in autism

Novartis seeks European marketing authorization for Myfortic

Boston Life Sciences' Troponin I passes toxicology tests

Meningitis vaccines near commercialization in Canada

Milestone in ALX-0646 migraine program

Phase III results for Aldurazyme support marketing approval application

Second Phase I grant awarded to Metabasis for liver disease research

Vaccines for chronic diseases jointly researched by Novartis and Cytos

Monoclonal antibody targeting human FLT-1 effective in human breast cancer xenograft model

AP-5280, a polymer-linked platinum antitumor agent, shows promising preclinical activity

XR-9576 tested in combination with vinorelbine in heavily pretreated cancer patients

First report of potent and selective inhibitors of c-Src protein tyrosine kinase identified at Ariad

Therapeutic antitumor potential of JNK inhibitors documented by Celgene

Ertapenem profiled at the IDSA meeting

Company Profile: TolerRx

Ranbaxy synthesizes new antifungal agents

Two patents cover GSK's new Raf kinase inhibitors and uses thereof

Inhibitors of FBPase useful for diabetes and related conditions

Potent LHRH antagonists with improved properties patented by Zentaris

Inhibitors of VLA-4-mediated cell adhesion disclosed by Aventis

New CB1 antagonists prepared by Aventis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...